Ceftazidime and avibactam is a combination antibiotic used to treat certain bacterial infections. It combines ceftazidime, a cephalosporin antibiotic, with avibactam, a beta-lactamase inhibitor. This pairing allows the drug to be effective against bacteria that produce enzymes, called beta-lactamases, which would normally break down ceftazidime alone [1].
How does ceftazidime and avibactam work?
Ceftazidime targets bacterial cell wall synthesis, weakening and eventually killing the bacteria. Avibactam protects ceftazidime from degradation by beta-lactamase enzymes, which are often responsible for antibiotic resistance in many types of bacteria, including common Gram-negative pathogens [1].
What infections is it used for?
This combination antibiotic is indicated for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) in patients 18 years of age and older who have limited or no alternative treatment options [1]. It is also used for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) [1].
When does the patent for ceftazidime and avibactam expire?
Drug patent expiration dates are crucial for understanding when generic versions may become available. Information regarding specific patent timelines for ceftazidime and avibactam can be found on DrugPatentWatch.com [2].
Who makes ceftazidime and avibactam?
The combination of ceftazidime and avibactam is marketed under the brand name Avycaz by its developers, GlaxoSmithKline (GSK) and Pfizer [1].
What are the alternatives to ceftazidime and avibactam?
Treatment options for resistant bacterial infections are continually evolving. Alternatives may include other beta-lactam/beta-lactamase inhibitor combinations, carbapenems, or other classes of antibiotics depending on the specific pathogen and its susceptibility profile. The choice of antibiotic is guided by local resistance patterns, patient factors, and clinical guidelines [1].
What clinical data supports its use?
Clinical trials have demonstrated the efficacy and safety of ceftazidime and avibactam in treating complicated UTIs, cIAIs, HABP, and VABP. Studies have shown favorable outcomes, including clinical cure rates and microbiological eradication of pathogens, particularly against multidrug-resistant organisms [1].
What are the risks and side effects?
Common side effects associated with ceftazidime and avibactam include nausea, vomiting, diarrhea, headache, and fever. More serious adverse reactions can include allergic reactions, Clostridioides difficile-associated diarrhea, and seizures. Patients should discuss any potential risks with their healthcare provider [1].
What is the regulatory status of this drug?
Ceftazidime and avibactam has received marketing authorization from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its approved indications [1].
How does it compare to other beta-lactam/beta-lactamase inhibitor combinations?
Other beta-lactam/beta-lactamase inhibitor combinations exist, such as meropenem-vaborbactam and imipenem-cilastatin-relebactam. Each combination has a different spectrum of activity, particularly against specific types of beta-lactamase enzymes, and is approved for particular indications. The selection of one over another depends on the identified pathogen and its resistance mechanisms [1].
Can biosimilars be developed for ceftazidime and avibactam?
The development of biosimilars for complex biologic drugs is a different process than for small-molecule drugs. Ceftazidime and avibactam is a combination of two small-molecule drugs. Once patents expire and regulatory hurdles are met, generic versions of this combination could potentially be developed [2].
---
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/drug/ceftazidime-avibactam